NCT04920370View on ClinicalTrials.gov

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions
Healthy
Interventions
DRUG

ALXN1720 SC

ALXN1720 will be administered via SC route.

DRUG

ALXN1720 IV

ALXN1720 will be administered via IV route.

DRUG

rHuPH20

rHuPH20 will be administered via SC route.

DRUG

Placebo SC

Placebo will be administered via SC route.

DRUG

Placebo IV

Placebo will be administered via IV route.

Trial Locations (1)

Unknown

Clinical Study Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY